Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2016 / Cilt: 25 - Sayı: 3

CA 125 Elevation Due to Minimal Change Disease

Minimal Değişiklik Hastalığına Bağlı CA 125 Yüksekliği

Pages
341–344
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our case, we determined the reason of the approximately thirty times elevated CA 125 levels as the nephrotic syndrome We wanted to mention that even at these high levels, one should consider that the reason of the elevation of CA 125 may be nephrotic syndrome, not a malignant condition

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Minimal change disease is a glomerular disease that can be primary or secondary and accounts for %1015 percent of adult nephrotic syndrome cases.
📊
Key Findings & Data:Measurement of the serum concentration of the CA 125 glycoprotein antigen is the most widely used biochemical method of screening for ovarian cancer but the specificity of this method is limited.
💡
Conclusion & Impact:In our case, we determined the reason of the approximately thirty times elevated CA 125 levels as the nephrotic syndrome We wanted to mention that even at these high levels, one should consider that the reason of the elevation of CA 125 may be nephrotic syndrome, not a malignant condition
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Minimal change disease is a glomerular disease that can be primary or secondary and accounts for %1015 percent of adult nephrotic syndrome cases. Measurement of the serum concentration of the CA 125 glycoprotein antigen is the most widely used biochemical method of screening for ovarian cancer but the specificity of this method is limited. Mean CA 125 levels further vary with ethnicity and smoking status and increase with age. CA 125 levels are elevated in approximately 1 percent of healthy women and fluctuate during the menstrual cycle. Levels of CA 125 increase in a variety of conditions other than ovarian pathologies. In our case, we determined the reason of the approximately thirty times elevated CA 125 levels as the nephrotic syndrome We wanted to mention that even at these high levels, one should consider that the reason of the elevation of CA 125 may be nephrotic syndrome, not a malignant condition

Özet

Minimal değişiklik hastalığı, primer veya sekonder olarak gelişebilen,erişkin dönem nefrotik sendrom olgularının %10-15'ine neden olan glomerüler bir hastalıktır. CA 125 glikoprotein antijeninin serum konsantrasyonunun ölçümü, over kanserleri için en sık kullanılan, ancak spesivitesi sınırlı bir biyokimyasal takip yöntemidir. Ortalama CA 125 seviyeleri, etnisite ve sigara içme durumuna göre değişiklik gösterir ve yaşla birlikte artar. Seviyeleri, sağlıklı kadınların yaklaşık %1'inde yüksek saptanabilmekte, menstrüel siklus boyunca dalgalanma göstermekte, over patolojileri dışında birçok durumda da yüksek saptanabilmektedir. Olgumuzda, 19 yaşında kadın hastada yaklaşık otuz kat kadar artmış CA 125 yüksekliğinin nedeni olarak nefrotik sendrom saptandı. Ayırıcı tanılar arasında, bu kadar yüksek değerlerde dahi nefrotik sendromun akılda tutulması gerektiğini vurgulamayı amaçladık

🔖

Cite This Article

MERCANTAŞ, E., VASİ, İ., ŞAHİN, G., BOZACI, İ. (2022). CA 125 Elevation Due to Minimal Change Disease. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 25 - Sayı: 3, 341–344. https://ajindex.com/articles/636179

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Cameron JS: The nephrotic syndrome and its complications. Am J Kidney Dis 1987;10:157-171
  2. Fogo A, Hawkins EP, Berry PL, Glick AD, Chiang ML, MacDonell RC Jr, Ichikawa I: Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 1990;38:115-123
  3. Schnaper HW, Robson AA, Kopp JB: Nephrotic syndrome: Minimal change nephropathy, focal segmental glomerulosclerosis, and collapsing glomerulopathy. In: Schrier RW (ed), Diseases of the Kidney and Urinary Tract (8th ed). Philadelphia: Lippincott Williams & Wilkins, (2007);1585 Shirato I: Podocyte process effacement in vivo. Microsc Res Tech 2002; 57:241-246 Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 1974;2:556-560
  4. Sellier-Leclerc AL, Duval A, Riveron S, Macher MA, Deschenes G, Loirat C, Verpont MC, Peuchmaur M, Ronco P, Monteiro RC, Haddad E: A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 2007;18:2732-2739
  5. Carlson KJ, Skates SJ, Singer DE: Screening for ovarian cancer. Ann Intern Med 1994;121:124-132
  6. Boix E, Rivera F, Gil CM, Peres-Conteras J, Olivares J: Steroid- responsive nephrotic syndrome with minimal-change disease and IgA deposits in a HIV-infected patient. Nephrol Dial Transplant 2000;15:412-414
  7. Lai KN, Lai FM, Chan KW, Ho CP, Leung AC, Vallance-Oven J: An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am J Clin Pathol 1986;86:716-723
  8. Cheng IK, Chan KW, Chan MK: Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: Disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis 1989;14:361-364
  9. Westhoff TH, Waldherr R, Loddenkemper C, Ries W, Zidek W, van der Giet M: Mesangial IgA deposition in minimal change nephrotic syndrome: Coincidence of different entities or variant of minimal change disease? Clin Nephrol 2006;65:203-207
  10. Sugase T, Akimoto T, Iwazu Y, Yamazaki T, Numata A, Takemoto F, Muto S, Kusano E: Minimal change nephrotic syndrome complicated with malignant ascites in a patient with type II diabetes. Intern Med 2012;51:1885-1888